Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse

Despite the excellent survival of Wilms tumour patients treated with multimodality therapy, approximately 15% will suffer from tumour relapse, where response rates are markedly reduced. We have carried out microarray‐based comparative genomic hybridisation on a series of 76 Wilms tumour samples, enriched for cases which recurred, to identify changes in DNA copy number associated with clinical outcome. Using 1Mb‐spaced genome‐wide BAC arrays, the most significantly different genomic changes between favourable histology tumours that did (n = 37), and did not (n = 39), subsequently relapse were gains on 1q, and novel deletions at 12q24 and 18q21. Further relapse‐associated loci included losses at 1q32.1, 2q36.3‐2q37.1, and gain at 13q31. 1q gains correlated strongly with loss of 1p and/or 16q. In 3 of 11 cases with concurrent 1p−/1q+, a breakpoint was identified at 1p13. Multiple low‐level sub‐megabase gains along the length of 1q were identified using chromosome 1 tiling‐path arrays. One such recurrent region at 1q22‐q23.1 included candidate genes RAB25, NES, CRABP2, HDGF and NTRK1, which were screened for mRNA expression using quantitative RT‐PCR. These data provide a high‐resolution catalogue of genomic copy number changes in relapsing favourable histology Wilms tumours. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  R. Bentley,et al.  Decreased E-cadherin expression correlates with higher stage of Wilms' tumors. , 2005, Journal of pediatric surgery.

[2]  Emmanuel Barillot,et al.  Analysis of array CGH data: from signal ratio to gain and loss of DNA regions , 2004, Bioinform..

[3]  J. Mulvihill,et al.  Chromosome 2q terminal deletion: Report of 6 new patients and review of phenotype‐breakpoint correlations in 66 individuals , 2004, American journal of medical genetics. Part A.

[4]  Toshio Kuroki,et al.  Role of Smad4 (DPC4) inactivation in human cancer. , 2003, Biochemical and biophysical research communications.

[5]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[6]  M. Coppes,et al.  Management of Wilms' tumour: current practice and future goals. , 2004, The Lancet. Oncology.

[7]  Kenny Q. Ye,et al.  Large-Scale Copy Number Polymorphism in the Human Genome , 2004, Science.

[8]  A. Cnaan,et al.  Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Russ B. Altman,et al.  Missing value estimation methods for DNA microarrays , 2001, Bioinform..

[10]  S. Blaschke,et al.  Expression of cadherin‐8 in renal cell carcinoma and fetal kidney , 2002, International journal of cancer.

[11]  D. Gisselsson,et al.  Wilms tumors develop through two distinct karyotypic pathways. , 2004, Cancer genetics and cytogenetics.

[12]  C. Croce,et al.  miRNAs, Cancer, and Stem Cell Division , 2005, Cell.

[13]  Simon Rogers,et al.  Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines , 2004, Genes, chromosomes & cancer.

[14]  P. Scambler,et al.  Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. , 1998, British Journal of Cancer.

[15]  C. Langford,et al.  Comprehensive DNA copy number profiling of meningioma using a chromosome 1 tiling path microarray identifies novel candidate tumor suppressor loci. , 2005, Cancer research.

[16]  Y. Yatabe,et al.  A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. , 2005, Cancer research.

[17]  Gerald C. Chu,et al.  TGFβ superfamily signals are required for morphogenesis of the kidney mesenchyme progenitor population , 2004, Development.

[18]  Ximing J. Yang,et al.  Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. , 2002, Cancer research.

[19]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[20]  E. Eichler,et al.  Fine-scale structural variation of the human genome , 2005, Nature Genetics.

[21]  A. Kelsey,et al.  Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. , 2002, Medical and pediatric oncology.

[22]  N. Breslow,et al.  High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. , 1999, Cancer research.

[23]  D. Govender,et al.  Microsatellite analysis of the DCC gene in nephroblastomas: pathologic correlations and prognostic implications , 2004, Modern Pathology.

[24]  M. Gessler,et al.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. , 2001, The American journal of pathology.

[25]  K. Gow,et al.  Cytogenetic and histologic findings in Wilms' tumor. , 2002, Journal of pediatric surgery.

[26]  N Breslow,et al.  Epidemiology of Wilms tumor. , 1993, Medical and pediatric oncology.

[27]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[28]  J. Barber,et al.  Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. , 2003, American journal of human genetics.

[29]  S. S. Young,et al.  Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .

[30]  A. Ashworth,et al.  Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity , 2005, The Journal of pathology.

[31]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[32]  Jane Fridlyand,et al.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. , 2005, Human molecular genetics.

[33]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[34]  Carlos Caldas,et al.  A Recurrent Chromosome Breakpoint in Breast Cancer at the NRG1/Neuregulin 1/Heregulin Gene , 2004, Cancer Research.

[35]  N. Breslow,et al.  Loss of Heterozygosity for Chromosomes 16q and Ip in Wilms' Tumors Predicts an Adverse Outcome' , 2022 .

[36]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[37]  D. Green,et al.  The treatment of stages I-IV favorable histology Wilms' tumor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N. Breslow,et al.  Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Williams,et al.  Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia , 2005, Oncogene.

[40]  G. Mills,et al.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.

[41]  P. Goodfellow,et al.  16q loss of heterozygosity and microsatellite instability in Wilms' tumor. , 2000, Journal of pediatric surgery.

[42]  A. Reeve,et al.  A gene expression signature for relapse of primary wilms tumors. , 2005, Cancer research.

[43]  Yong-jie Lu,et al.  Chromosome 1q expression profiling and relapse in Wilms' tumour , 2002, The Lancet.

[44]  Shaying Zhao,et al.  1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. , 2003, Genome research.

[45]  D. Welch,et al.  KISS1 metastasis suppression and emergent pathways , 2004, Clinical & Experimental Metastasis.

[46]  D. Schofield,et al.  Identification of the neurotrophin receptors p75 and trk in a series of Wilms' tumors. , 1994, The American journal of pathology.